The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Agios Pharmaceuticals Inc shares valued at $214,642 were sold by FOUSE JACQUALYN A on Apr 10 ’24. At $27.55 per share, FOUSE JACQUALYN A sold 7,791 shares. The insider’s holdings dropped to 137,396 shares worth approximately $4.11 million following the completion of this transaction.
Also, Foster-Cheek Kaye I sold 1,285 shares, netting a total of over 40,632 in proceeds. Following the sale of shares at $31.62 each, the insider now holds 5,524 shares.
Before that, Foster-Cheek Kaye I had sold 4,415 shares from its account. In a trade valued at $141,236, the Director traded Agios Pharmaceuticals Inc shares for $31.99 each. Upon closing the transaction, the insider’s holdings decreased to 4,415 shares, worth approximately $0.2 million.
As published in their initiating research note from Cantor Fitzgerald on February 08, 2024, Agios Pharmaceuticals Inc [AGIO] has been an Overweight. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in early February. As of November 17, 2022, Goldman has increased its “Sell” rating to a “Neutral” for AGIO. Earlier on July 27, 2022, SVB Leerink upgraded its rating. Their new recommendation was “an Outperform” for AGIO stock which previously was a “a Mkt perform”.
Analyzing AGIO Stock Performance
During the last five days, there has been a surge of approximately 5.16%. Over the course of the year, Agios Pharmaceuticals Inc shares have jumped approximately 34.44%. Shares of the company reached a 52-week high of $35.50 on 02/27/24 and a 52-week low of $20.96 on 01/19/24. A 50-day SMA is recorded $28.59, while a 200-day SMA reached $25.41. Nevertheless, trading volume fell to 0.74 million shares from 0.73 million shares the previous day.
Support And Resistance Levels for Agios Pharmaceuticals Inc (AGIO)
According to the 24-hour chart, there is a support level at 29.24, which, if violated, would cause prices to drop to 28.54. In the upper region, resistance lies at 30.45. The next price resistance is at 30.96. RSI (Relative Strength Index) is 56.36 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.11, which suggests the price will decrease in the coming days. Percent R is at 35.48%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Agios Pharmaceuticals Inc subject to short interest?
Stocks of Agios Pharmaceuticals Inc saw a sharp steep in short interest on Mar 15, 2024 dropping by -0.8 million shares to 6.85 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 7.65 million shares. A decline of -11.68% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.11 of the overall float, the days-to-cover ratio (short ratio) decline to 7.11.
